A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy

Jianjun Liu1,*, Mingxue Su2,*, Jing Wang3,*, Gan Zhang1, Jing Zhou1, Anqing Zhang1, Zixue Ren1, Xucai Zheng1, Shikai Hong1, Shengying Wang1 and Rongxin Zhang1

1 Department of Head - Neck and Thoracic Surgery, Anhui Provincial Cancer Hospital, West branch of Anhui Province Hospital, Hefei, China
2 Department of Infectious Disease Epidemiology, Lu’an People’s Hospital, Lu’an, China
3 Department of Urologic Surgery, Anhui Provincial Cancer Hospital, West branch of Anhui Province Hospital, Hefei, China

* These authors have contributed equally to this work

Correspondence to: Rongxin Zhang, email: rongxzhang@126.com
Correspondence to: Shengying Wang, email: Shengywang@163.com

Keywords: neoadjuvant radiotherapy; gastric cancer; survival analysis; SEER

Received: August 23, 2016 Accepted: October 05, 2016 Published: October 11, 2016

ABSTRACT

Although local advanced gastric cancer (AGC) could benefit from neoadjuvant radiotherapy (NRT), there are few studies evaluating patients’ survival after NRT. In current study, we aimed to investigate the value of prognostic factors in AGC patients after NRT and to evaluate whether post-therapy pathological characteristics were predictive factors in these patients. We retrospectively analyzed AGC patients who underwent NRT from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clinical and post-therapy pathological characteristics were analyzed. The best cutoff points for continuous variables were identified by X-tile. The discrimination of risk factors were compared by receiver operating characteristic (ROC) curve. As a result, 1,429 AGC patients were included into this study. In the multivariate analysis, the lymph nodes status and histology grade were significant risk factors for DSS (disease specific survival). Then, we propose a novel Grade-lymph node Ratio (G-R) staging system for the AGC patients’ survival prognosis. Clearly, the new G-R staging system has a more-accurate 3-year and 5-year DSS prediction than the AJCC staging system ($p = 0.001, 0.007$, respectively). In conclusions, the current large, general population-based study demonstrated that the G-R staging system resulting in more-accurate DSS prediction. It could be regarded as a reliable classification for AGC patients after NRT in future.

INTRODUCTION

Gastric cancer is the fourth most common malignancy and second leading cause of cancer-related death worldwide. [1] In 2014, approximately 22,220 new cases were diagnosed and 10,990 deaths attributed to gastric cancer in United States. Although the incidence has declined recently, the 5-year survival was less than 30%. [2, 3]

Completed resection with lymph node dissection is the only potential curative treatment for resectable cancer. [4] However, the cancer symptoms usually were not obvious in early stage, most patients were diagnosed with advanced stage in most countries. Recently, the MAGIC trials demonstrated that the neoadjuvant chemotherapy improved survival for AGC patients. [5] Meanwhile, several phase I/II trails also demonstrated a survival benefit for AGC patients after NRT. [6-8] Indeed, the neoadjuvant therapy can achieve a clinical downstaging before resection and increase the possibility of R0 resection for AGC patients. [9-11] As a result, the neoadjuvant therapy were widely used for potentially resectable AGC before surgery.

Based on those promising results, the neoadjuvant...
| Characteristic            | Patients(n = 1,429) |     | %  |
|---------------------------|---------------------|-----|----|
| Age (years)               |                     |     |    |
| Median                    |                     |     | 60.8±10.4 |
| Range                     |                     |     | 14 to 88 |
| Gender                    |                     |     |    |
| Male                      | 1206                |     | 84.4 |
| Female                    | 223                 |     | 15.6 |
| Race                      |                     |     |    |
| White                     | 1278                |     | 89.4 |
| Black                     | 61                  |     | 4.3 |
| AI                        | 18                  |     | 1.3 |
| API                       | 70                  |     | 4.9 |
| Unknown                   | 2                   |     | 0.1 |
| Tumor size (cm)           |                     |     |    |
| Median(n = 1027)          |                     |     | 4.6±3.4 |
| Range                     |                     |     | 0.1 to 50 |
| Tumor location            |                     |     |    |
| Cardia                    | 1299                |     | 90.9 |
| Fundus                    | 9                   |     | 0.6 |
| Body                      | 17                  |     | 1.2 |
| Antrum                    | 32                  |     | 2.2 |
| Pylorus                   | 4                   |     | 0.3 |
| Lesser curvature          | 29                  |     | 2.0 |
| Greater curvature         | 9                   |     | 0.6 |
| Overlapping               | 18                  |     | 1.3 |
| Unknown                   | 12                  |     | 0.8 |
| Grade                     |                     |     |    |
| Well differentiated       | 62                  |     | 4.3 |
| Moderately differentiated | 510                 |     | 35.7 |
| Poorly differentiated     | 827                 |     | 57.9 |
| Undifferentiated          | 30                  |     | 2.1 |
| Depth of invasion         |                     |     |    |
| Mucosa or submucosa       | 134                 |     | 9.4 |
| Proper muscle             | 215                 |     | 15.0 |
| Subserosa                 | 667                 |     | 46.7 |
| Serosa                    | 260                 |     | 18.2 |
| Adjacent invasion         | 125                 |     | 8.7 |
| Unknown                   | 28                  |     | 2.0 |
| Number of positive LN.    |                     |     |    |
| 0                         | 757                 |     | 53.0 |
| 1 to 2                    | 342                 |     | 23.9 |
| 3 to 6                    | 231                 |     | 16.2 |
| 7 to 15                   | 81                  |     | 5.7 |
| 16 or more                | 18                  |     | 1.3 |
| Positive LN (Mean±SD)     |                     |     | 1.8±3.3 |
| Total LN (Mean±SD)(n=1411)|                     |     | 14.3±9.9 |
| AJCC Stage                |                     |     |    |
| IA                        | 100                 |     | 7.0 |
therapy may be a potential standard treatments for AGC patients. However, the prognostic value of post-therapy pathologic characteristic were still unclear, especially in patients underwent NRT. [10, 12-15] In current study, we aimed to investigate the value of prognostic factors in AGC patients and to evaluate whether post-therapy pathological characteristics were predictive factors of survival in these patients.

RESULTS

Patients and demographics

A total of 1,429 patients between January 1998 and November 2013 in the SEER database who met all the inclusion criteria were analyzed in current study. The patients’ characteristics were listed in Table 1. Overall, there were 1,206 male patients and 223 female patients, and the median age was 60.8 years old. There were also 60 (4.2%) patients who received adjuvant radiotherapy after curative resection. The mean number of positive lymph node was 1.8±3.3, and the mean total examined number of lymph node was 14.3±9.9. With a median follow-up of 31.9 months, there were 760 (53.2%) patients died before the analysis of the present study, and 102 (13.4%) patients of them were died because of other causes.

Survival and lymph node ratio categories

The median DSS for all patients was 35 months, and the 1-year DSS, 3-year DSS, 5-year DSS were 83.0%, 48.9% and 39.0%, respectively. Lymph node ratio was

| IB    | 146 | 10.2 |
|-------|-----|------|
| IIA   | 410 | 28.7 |
| IIB   | 307 | 21.5 |
| IIIA  | 196 | 13.7 |
| IIIB  | 173 | 12.1 |
| IIIC  | 69  | 4.8  |
| Unknown | 28 | 2.0  |

Abbreviations: AI, American Indian or Alaska Native; API, Asian or Pacific Islander; LN, lymph node; AJCC, American Joint Committee on Cancer.

Figure 1: X-tile analysis identified the best cutoff points for mLNR A., and validated by Kaplan-Meier Curve B. Abbreviation: mLNR, metastatic lymph node ratio.
Table 2: Prognostic factors for DSS of all the patients

|                          | Univariate analysis | Multivariate Analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR                  | 95% CI                | p         | HR                  | 95% CI                | p         |
| Age                      | 1.005               | 0.998 to 1.013        | 0.167     |                     |                      |           |
| Gender (Female / Male)    | 0.879               | 0.708 to 1.091        | 0.243     |                     |                      |           |
| Race                     |                     | 0.062                 |           |                     |                      |           |
| API/ nonAPI              | 0.762               | 0.573 to 1.014        |           |                     |                      |           |
| Location                 | 0.939               |                       |           |                     |                      |           |
| Antrum                   | ref                 |                       |           |                     |                      |           |
| Fundus                   | 0.771               | 0.220 to 2.707        |           |                     |                      |           |
| Body                     | 1.255               | 0.520 to 3.029        |           |                     |                      |           |
| Cardia                   | 1.336               | 0.771 to 2.315        |           |                     |                      |           |
| Pylorus                  | 1.464               | 0.417 to 5.139        |           |                     |                      |           |
| Lesser curvature         | 1.462               | 0.678 to 3.155        |           |                     |                      |           |
| Greater curvature        | 1.371               | 0.488 to 3.847        |           |                     |                      |           |
| Overlapping              | 1.547               | 0.661 to 3.620        |           |                     |                      |           |
| Grade                    |                     |                       |           | 0.010               |                      |           |
| Well/Moderately          | 0.714               | 0.608 to 0.838        | 0.807     | 0.686 to 0.950      | 0.638                 |           |
| Poorly differentiated/   |                     |                       |           |                     |                      |           |
| Undifferentiated         |                     |                       |           |                     |                      |           |
| Total LN                 | 1.002               | 0.994 to 1.010        | 0.584     | 0.807               | 0.686 to 0.950       | 0.638                 |           |
| Tumor Size (n = 1027)    | 1.001               | 0.999 to 1.004        | 0.414     | 0.807               | 0.686 to 0.950       | 0.638                 |           |
| Depth of invasion        |                     |                       |           |                     |                      |           |
| Mucosa or submucosa      | ref                 |                       |           |                     |                      |           |
| Proper muscle            | 1.106               | 0.797 to 1.535        |           |                     |                      |           |
| Subserosa                | 1.068               | 0.800 to 1.424        |           |                     |                      |           |
| Serosa                   | 1.304               | 0.964 to 1.765        |           |                     |                      |           |
| Adjacent invasion        | 1.549               | 1.105 to 2.173        |           |                     |                      |           |
| mLNR stage.              |                     |                       |           | 0.010               | 0.638                 |           |
| 0                        | ref                 |                       |           | ref                 |                      |           |
| 1                        | 1.522               | 1.233 to 1.879        | 1.496     | 1.209 to 1.851      | 1.522               | 1.233 to 1.879 | 1.496     | 1.209 to 1.851 |
| 2                        | 2.378               | 1.910 to 2.962        | 2.295     | 1.834 to 2.872     | 2.378               | 1.910 to 2.962 | 2.295     | 1.834 to 2.872 |
| 3                        | 3.413               | 2.779 to 4.191        | 2.269     | 2.648 to 4.036     | 3.413               | 2.779 to 4.191 | 2.269     | 2.648 to 4.036 |
| Adjuvant radiotherapy (ART/ no-ART) | 0.948 | 0.795 to 1.129 | 0.546 |

Abbreviations: HR: hazard ratio; API, Asian or Pacific Islander; LN, lymph node; mLNR: metastatic lymph node ratio; ART: Adjuvant radiotherapy.

defined as the number of positive nodes divided by the total examined nodes. As shown in the Figure 1, the best cutoff points for mLNR were 17.0% and 38.0%. Therefore, the mLNR were classified into four groups, as the following intervals. The mLNRs 0: mLNR = 0%; mLNRs 1: 0% < mLNR < 17.0%; mLNRs 2: 17.0% < mLNR < 38.0%; mLNRs 3: 38.0% < mLNR < 100%. 5-year DSS for the 4-level mLNR were 52.1%, 36.8%, 14.8% and 10.4%, respectively.
Analysis of post-therapy prognostic factors

In the univariate analysis, the depth of invasion, grade and mLNRs were significant risk factors for AGC after NRT, whereas, other factors such as age, gender, race, location, total examined lymph node (TLN) were not correlated with DSS. However, in the multivariate analysis, the depth of invasion lost statistical significance as a prognostic factor ($p = 0.638$).

According to the Cox regression analysis, we divided the patients into 8 groups (Group 1: mLNRs 0 and Grade I-II; Group 2: mLNRs 0 and Grade III-IV; Group 3: mLNRs 1 and Grade I-II; Group 4: mLNRs 1 and Grade III-IV; Group 5: mLNRs 2 and Grade I-II; Group 6: mLNRs 2 and Grade III-IV; Group 7: mLNRs 3 and Grade I-II; Group 8: mLNRs 3 and Grade III-IV) based on grade and mLNRs (Figure 2A). However, as shown in Figure 2A, there was no significant difference between Group 3 and 4 (log rank $p = 0.768$), and also have insignificant difference in Group 5, 6 and 7 (log rank $p = 0.955$). As a result, we propose a novel Grade-lymph node Ratio (G-R) staging system for all the AGC patients after NRT (As shown in Figure 2B). The G-R 1 was defined as mLNR equal to 0% and Grade I-II; G-R 2 as mLNR equal to 0% and Grade III-IV; G-R 3 as mLNRs 1; G-R 4 as mLNRs 2, or mLNRs 3 with Grade I-II; G-R 5 as mLNRs 3 and Grade III-IV. The observed 5-year DSS curves based G-R staging was shown in Figure 2B.

Comparison of predictive accuracy for G-R staging system single independent factors and AJCC staging system

The Area Under the ROC Curve (AUC) values were used to compare the discrimination for the G-R staging system and other prognostic models (mLNRs, AJCC staging system). The statistics power for discrimination between G-R staging system and AJCC staging system were compared in each time points. As shown in Table 3 and Figure 3, the AUC of G-R staging system were higher than mLNRs and AJCC staging system in both 3-year and 5-year time points ($p = 0.001, 0.007$, respectively). Whereas, the AUC of G-R staging system were higher than AJCC staging system 1-year DSS but did not reach statistical significance ($p = 0.282$).

DISCUSSION

In the present study, we developed a novel G-R staging system for AGC patients after NRT. A total of 1,429 AGC patients who received surgery following NRT from SEER database between 1998 and 2012 were analyzed. We demonstrated that the new G-R staging system has a more-accurate 3-year and 5-year DSS prediction than the AJCC staging system ($p$ value, $< 0.001, 0.008$, respectively).

The survival benefit of neoadjuvant therapy had been investigated in various tumors, including esophageal, pancreatic and rectal cancers. [16-18] However, the prognostic value of post-therapy pathological

Figure 2: A. The patients were grouped into 8 groups and validated Kaplan-Meier Curve. B. The patients were grouped into 5 groups and validated Kaplan-Meier Curve. Abbreviation: mLNRs, metastatic lymph node ratio stage; G-R stage, Grade-lymph node Ratio.
Figure 3: Comparison for the AUC of G-R staging system predicted, AJCC staging system and mLNRs to predict DSS at 1-year A., 3-year B., 5-year C. Abbreviation: AUC, areas under the receiver operating curves; mLNRs, metastatic lymph node ratio stage; G-R stage, Grade-lymph node Ratio; DSS, disease special survival.
The G-R staging system appeared to have a more-accurate DSS prediction than AJCC staging system or single independent factors. Since approximately 50% of the gastrectomy cases included in the SEER database came from community institutions, it is inconceivable that the G-R staging system has a broader applicability. [20]

The completed (R0) resection with D2 lymphadenectomy was the only potential curative for GC patients. [4] Since resection with D2 lymphadenectomy had not been widely performed in United States, the variable whether the patient received D2 lymphadenectomy was not included in this study. Additionally, although the previous studies demonstrated that the R0 resection was a significant risk for patients' survival, such direct evidence is unavailable because that SEER database did not collect the information of gastrectomy surgical margin status. [21] Given that the current study was a retrospective study, only the patients who had complete information were included in present analysis, there may be a selection bias. In addition, in the univariate analysis and multivariate analysis, the number of positive lymph node was also associated with patient’s survival. The discrimination of mLNRs was better than that of positive lymph node number, but the difference was insignificant (data not shown). Given that the positive lymph nodes number identified depends on the pathologic procedure and surgical scope, we used mLNRs instead of positive lymph nodes number in the new classifier. [22]

Since the G-R staging system have a more-accurate survival prediction, it would be favor for designing postoperative treatment, particularly, which stage patients can obtain survival benefit from adjuvant radiotherapy after surgery. However, the difference of adjuvant radiotherapy were not correlated with DSS in each G-R stages (detailed data unshown). However, these findings should be interpreted with caution. The reasons are as follows: Firstly, there is missing information regarding the use of adjuvant chemotherapy. It is possible that patients may have received adjuvant chemotherapy after surgery, resulting in a potential confounder in this study. Secondly, the possibility of selection bias could be acknowledged, since the current analysis was not based on a randomized patient population. Thirdly, since there were only 60 patients underwent adjuvant radiotherapy included in this

---

**Table 3: Comparison of predictive accuracy of DSS for G-R staging system, single independent factor and the 7th AJCC staging system in each time points**

| Time points | G-R staging system | mLNR stage | AJCC staging system |
|-------------|--------------------|------------|---------------------|
|             | AUC 95%CI          | AUC 95%CI  | AUC 95%CI           | P*                  |
| 1-Year      | 0.635 0.592 to 0.679 | 0.623 0.579 to 0.666 | 0.603 0.559 to 0.647 | 0.282              |
| 3-Year      | 0.701 0.668 to 0.735 | 0.685 0.651 to 0.720 | 0.619 0.583 to 0.656 | 0.001              |
| 5-Year      | 0.699 0.661 to 0.738 | 0.683 0.644 to 0.721 | 0.619 0.575 to 0.662 | 0.007              |

*: The p value in the AUC were the G-R staging model compared with AJCC staging system.
study, it may lead to a bias result.

In conclusion, the current large, general population-based study demonstrated that the post-therapy pathological characteristics were associated with the survival of AGC patients after NRT. The post-therapy grade and mLNR were the only two predictors for those patients. Based on this finding, the novel G-R staging system showed optimal accuracy of survival prediction for AGC patients after neoadjuvant therapy. Through this classifier, clinicians can estimate the survival of the AGC patients after NRT more precisely.

METHODS AND PATIENTS

Surveillance, epidemiology, and end results (SEER) database

The SEER program, a large population-based collaboration program, was surveyed by the National Cancer Institute. A total of 18 population-based cancer registries were participated in this program, and the data are updated annually. It collects and provides approximately 26% American population’s cancer incidence and survival data.

Gastric cancer (ICD-O-3 code within the range of 8000-8152, 8154-8231, 8243-8245, 8250-8576, 8940-8950, and 8980-8990) undergoing NRT between January 1998 and December 2012 were eligible for current study. The inclusion criteria were as follows: 1) Patients without distant metastasis; 2) patients received gastrectomy (Surgery code within the range of 30-80); 3) patients received radiotherapy before surgery.

Statistical methods

The data of patients’ clinicopathological characteristics such as age at diagnosis, gender, race, marital status, surgery, tumor site, size, histology, grade, depth of invasion, number of positive lymph node (PLN) and TLN were collected. The primary endpoint was DSS, which was defined as the time form surgery to cancer-related death or the last follow-up. The pathological characteristics depth of invasion, lymph nodal stage and tumor stage were restaged according to the 7th edition AJCC staging system.

Tumor grade is a measurement of how closely the tumor cells resemble the normal gastric cancer. Well-differentiated (Grade I) and moderately-differentiated (Grade II) tumor cells closely resemble the tissue from normal gastric, whereas, poorly-differentiated (Grade III) and undifferentiated (Grade IV) tumor cells are disorganized and abnormal looking.

The mLNR was defined as the number of metastatic lymph nodes divided by the number of examined lymph nodes. A unique category mLNRs 0 was defined for patients with no regional positive lymph node, since those patients had significantly better prognosis than other patients ($HR = 0.48, p < 0.001$). The patients with mLNR higher than 0% were categorized by X-tile (http://www.tissuearray.org/rimmlab/). By this statistic tool, the continuous variables can divide into three groups. Associations between each group can be calculated by various standard statistical tests, including the log-rank test for survival and means tests for associations between other marker data. The X-tile can provide the optimal division of the data by p values obtained from a lookup table [23]

Independent risk factors were identified by the Cox regression analysis. DSS estimation and survival curves were performed by the Kaplan-Meier method and validated by the log-rank test. The Discrimination between the proposed G-R staging system and AJCC staging system was performed with ROC curve.

All analyses were performed by the software statistical package for social sciences (SPSS) version 19.0 (Chicago, IL), X-tile and the R software version 3.13 (http://www.r-project.org/). All the statistical tests were two sided. $p$ value $< 0.05$ was considered to be statistically significant.

ACKNOWLEDGMENTS

The authors thank our colleagues from the Department of Head - neck and Thoracic Surgery for their kind help.

CONFLICTS OF INTEREST

The authors have no potential conflicts of interest.

GRANT SUPPORT

None.

Authors’ Contributions

Conception and design: Shengying Wang, Rongxin, Zhang, Jianjun Liu

Development of methodology: Shengying Wang, Rongxin, Zhang

Collection and assembly of data: Jianjun Liu, Mingxue Su

Data analysis and interpretation: Jianjun Liu, Mingxue Su

Writing, review, and/or revision of the manuscript:

All authors

Administrative, technical, or material support: Shengying Wang, Rongxin, Zhang

Study supervision: Shengying Wang, Rongxin,
REFERENCES

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jamal A. Cancer treatment and survivorship statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:252-271.

2. Parkin DM. Global cancer statistics in the year 2000. The Lancet Oncology. 2001; 2:533-543.

3. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M and La Vecchia C. Recent patterns in gastric cancer: a global overview. International journal of cancer. 2009; 125:666-673.

4. Songun I, Putter H, Kranenbarg EM, Sasako M and van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology. 2010; 11:439-449.

5. Cunningham D, Allum WH, Stening SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ and Participants MT. Perioperative chemoradiotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006; 355:11-20.

6. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS and Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. Journal of clinical oncology. 2004; 22:2774-2780.

7. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C and Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. Journal of clinical oncology. 2006; 24:3953-3958.

8. Trip AK, Poppema BJ, van Berge Henegouwen MI, Siemerink E, Beukema JC, Verheij M, Plukker JT, Richel DJ, Hulshof MC, van Sandick JW, Cats A, Jansen EP and Hospers GA. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014; 112:284-288.

9. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Rajimah I, Hargraves K, Curley S and Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. Journal of clinical oncology. 1999; 17:2403-2411.

10. Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC and Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. Journal of gastrointestinal oncology. 2015; 6:534-543.

11. Yang Y, Yin X, Sheng L, Xu S, Dong L and Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Scientific reports. 2015; 5:12850.

12. Fujitani K, Mano M, Hirao M, Kodama Y and Tsujinaka T. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Annals of surgical oncology. 2012; 19:1936-1943.

13. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P and Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999; 229:303-308.

14. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J and Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. Journal of clinical oncology. 2005; 23:1237-1244.

15. An JY, Kim HI, Cheong JH, Hyung WJ, Kim CB and Noh SH. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei medical journal. 2013; 54:888-894.

16. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR and Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103:1347-1355.

17. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW and Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Annals of surgical oncology. 2001; 8:123-132.

18. Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, Paty PB, Wong WD, Larson SM, Cohen AM and Guillem JG. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Annals of surgery. 2002; 236:75-81.

19. Edge SB BD CC, Fritz AG et al. AJCC Cancer Staging Manual 7th. Springer. 2010; New York.

20. Hoffman KE, Neville BA, Mamon HJ, Kachnic LA, Kachnic MS, Earle CC and Punglia RS. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer. 2012; 118:248-257.

21. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, van Meyenfeldt MF and Tilanus H. Extended
lymph-node dissection for gastric cancer. The New England Journal of Medicine. 1999; 340:908-914.

22. Wang W, Xu DZ, Li YF, Guan YX, Sun XW, Chen YB, Kesari R, Huang CY, Li W, Zhan YQ and Zhou ZW. Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients. Annals of Oncology. 2011; 22:2049-2056.

23. Criminisi A SJ. Decision forests for computer vision and medical image analysis. Springer. 2013.